Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164169 | 0.91 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL29854483 | 0.87 | CYP3A4 (0.58) | CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL17294772 | 0.87 | BCHE (0.63) | — | |
| SCHEMBL17294638 | 0.87 | BCHE (0.63) | — | |
| SCHEMBL17294642 | 0.87 | BCHE (0.63) | — | |
| SCHEMBL19049149 | 0.86 | CHRM3 (0.58) | CHRM3 | |
| SCHEMBL14461279 | 0.86 | CHRM3 (0.57) | CHRM3 | |
| SCHEMBL17294662 | 0.84 | CYP2D6 (0.74) | CYP3A4CYP1A2CYP2D6CHRM3 | |
| SCHEMBL1739564 | 0.84 | CYP2D6 (0.74) | CYP3A4CYP1A2CYP2D6CHRM3 | |
| SCHEMBL1872978 | 0.84 | CYP2D6 (0.74) | CYP3A4CYP1A2CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | claimed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | claimed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | claimed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| CN-119954297-A | Rural domestic sewage treatment device and sewage treatment method based on SBR technology | 蚌埠学院 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024261775-A1 | A DRUG-ANTAGONIST COMBINATION DOSAGE FORM | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2024-12-26 | — | — | WO | disclosed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| CN-106659697-B | Compounds as antituberculosis agents | 斯菲叶尔制药私有公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210046014-A1 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION CONSTRUCTED IN MORE THAN ONE STRENGTHS | Patel, Jayendrakumar Dasharathlal (IN) | 2021-02-18 | — | — | US | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008086804-A2 | USE OF I) A POLYGLYCOL AND N) AN ACTIVE DRUG SUBSTANCE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR I) MITIGATING THE RISK OF ALCOHOL INDUCED DOSE DUMPING AND/OR II) REDUCING THE RISK OF DRUG ABUSE | EGALET A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| US-20080075772-A1 | PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS | ACCU-BREAK TECHNOLOGIES, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1275645-B1 | LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM | HAMAMATSU PHOTONICS KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1275645-A1 | LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM | HAMAMATSU PHOTONICS K. K. (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | CYP3A4 527/4885CYP1A2 612/4885CYP2D6 865/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CYP3A4 1284/4885CYP1A2 1475/4885CYP2D6 1722/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CYP3A4 1284/4885CYP1A2 1475/4885CYP2D6 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.